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Tenofovir is an acyclic nucleotide analogue reverse-transcriptase inhibitor structurally similar to the nephrotoxic drugs adefovir
and cidofovir. Tenofovir is widely used to treat HIV infection and approved for treatment of hepatitis B virus. Despite initial cell
culture and clinical trials results supporting the renal safety of tenofovir, its clinical use is associated with a low, albeit significant,
risk of kidney injury. Proximal tubular cell secretion of tenofovir explains the accumulation of the drug in these mitochondria-
rich cells. Tenofovir nephrotoxicity is characterized by proximal tubular cell dysfunction that may be associated with acute kidney
injury or chronic kidney disease. Withdrawal of the drug leads to improvement of analytical parameters that may be partial.
Understanding the risk factors for nephrotoxicity and regular monitoring of proximal tubular dysfunction and serum creatinine in
high-risk patients is required to minimize nephrotoxicity. Newer, structurally similar molecular derivatives that do not accumulate
in proximal tubules are under study.
1. Tenofovir
Tenofovir disoproxil fumarate is an orally bioavailable pro-
drug of tenofovir, an acyclic nucleotide analogue reverse-
transcriptase inhibitor (NtRTI) structurally similar to ade-
fovir and cidofovir [1] (Figure 1). Acyclic nucleotides diﬀer
in their side chains: hydroxy phosphonomethoxypropyl
(HPMP) for cidofovir, phosphonomethoxyethyl (PME) for
adefovir and phosphonomethoxypropyl (PMP) for teno-
fovir [2]. Tenofovir diphosphate is a structural analog of
deoxyadenosine-5′-triphosphate, the usual substrate for viral
RNA-directed DNA polymerase, and is a weak inhibitor of
mammalian DNA α- and β-polymerases and mitochondrial
DNA γ-polymerase [3].
Tenofovir was the first (2001), and remains the only,
NtRTI approved by the US Food and Drug Administration
(FDA) for the treatment of HIV infection [1]. Tenofovir
was also approved for treatment of chronic hepatitis B
in adults in 2008 [4]. Tenofovir is now a widely used
component of antiretroviral regimens for both treatment-
naive and experienced patients on the basis of its eﬃcacy and
tolerability in clinical trials. US HIV treatment guidelines
considered tenofovir as part of all preferred regimens for
antiretroviral-naive adults and adolescents [5]. Tenofovir
is available in fixed-dose combination with emtricitabine
and efavirenz [6]. Up to the end of 2007, the cumulative
experience with tenofovir in Europe and North America was
around 455 392 person-years [7].
Tenofovir is eliminated unchanged in the urine by a
combination of glomerular filtration and proximal tubular
secretion [8]. 20–30% of the drug is actively transported into
renal proximal tubule cells by organic anion transporters
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(hOAT1, and to a lesser extent, OAT3) in the basolateral
membrane [9, 10]. Subsequently the drug is secreted to the
tubular lumen by the apical membrane transporters MRP-
4 and MRP-2 (multidrug resistance proteins, encoded by
ABCC4 and ABCC2 genes, resp.) [6] (Figure 2). A number
of drugs interact with these transporters and may cause
excessive entry or reduced outflow of the drug, favoring
intracellular accumulation and increasing renal toxicity
(Table 1).
Tenofovir has less adverse eﬀects on blood lipids, fat
accumulation, and mitochondrial toxicity than nucleoside
phosphonate reverse transcriptase inhibitors [12]. Gastroin-
testinal symptoms are the most common side eﬀects of
tenofovir [12]. Kidney toxicity may lead to acute kidney
injury (AKI), chronic kidney disease (CKD), and features
of proximal tubular injury, including Fanconi syndrome,
isolated hypophosphatemia, and decreased bone mineral
density (Figure 2) [13–17].
2. Tenofovir Nephrotoxicity
Concerns regarding nephrotoxicity were initially raised by
the structural similarity between tenofovir and the nephro-
toxic acyclic nucleotide analogues adefovir and cidofovir.
These two drugs cause a proximal tubulopathy, possibly in
part due to decreasing mitochondrial DNA (mtDNA) repli-
cation through inhibition ofmitochondrial DNApolymerase
γ [3, 18]. However, only minimal mtDNA depletion was
noted in renal proximal tubular cells cultured with tenofovir
[19]. Furthermore, early randomized clinical trials and
postmarketing data supported the renal safety of tenofovir in
relatively healthy HIV+ individuals [7, 20]. Neither Fanconi
syndrome nor drug discontinuation because of renal events
was observed in early trials [12, 21]. However, case reports,
observational studies, animal models, and even cell culture
data support the notion that tenofovir is nephrotoxic for
proximal tubular cells [22–27]. The mismatched results
between clinical trials and case reports may be explained
because clinical trials have strict inclusion and exclusion
criteria. By contrast in routine clinical practice patients may
have associated conditions, medications, or background that
may predispose to tenofovir nephrotoxicity [22]. We now
review the evidence for tenofovir nephrotoxicity and discuss
potential molecular mechanisms and clinical approaches.
3. Clinical Features of Tenofovir Nephrotoxicity
The main clinical presentations of tenofovir nephrotoxicity
are (a) proximal tubular dysfunction with preserved renal
function and (b) proximal tubular dysfunction associated
with decreased renal function. Decreased renal function may
be classified as AKI, CKD, or a glomerular filtration rate
(GFR) that is decreased when compared with baseline values,
albeit within normal limits. Currently available information
suggests that all of them share a basic common pathogenesis
and pathology, which will be discussed together.
Table 1: Drugs interfering with proximal tubular tenofovir trans-
porters.
Transporter Drug interaction Eﬀect
hOAT1
Probenecid inhibits
hOAT1
NSAIDs inhibit
hOAT1
Acyclovir
DDI competes with
tenofovir
Probenecid decreases
the incidence of renal
toxicity by cidofovir,
might for tenofovir
[28]
Acyclovir increases
serum concentrations
of tenofovir
Tenofovir increases
DDI levels [29]
MRP-4
Inhibition of MRP-4:
probenecid
dipyridamole
NSAIDs [30]
Acyclovir increase
serum concentrations
of tenofovir
NSAIDs associated
with tenofovir
nephrotoxicity
[30, 31]
Cidofovir, acyclovir,
valaciclovir,
ganciclovir, and
valganciclovir
MRP-2
Ritonavir is
transported by
MRP-2
Ritonavir increases
tenofovir
concentration and has
been associated with
tenofovir
nephrotoxicity
Most reported cases of tenofovir-associated nephropathy
identified a partial or complete Fanconi syndrome, asso-
ciated or not with a reduction in GFR [20, 22, 32–35].
Fanconi syndrome is a generalized proximal tubulopathy.
In its complete form it associates renal tubular acidosis,
glycosuria with normoglycemia, aminoaciduria, hypophos-
phatemia, hypouricemia, and tubular proteinuria [6, 23]
(Table 2). Tubular dysfunction may precede the decline of
renal function. Tubular proteinuria implies the presence in
urine of increased amounts of small-sized proteins that are
freely filtered in the glomerulus but reabsorbed by proximal
tubules. β2-microglobulinuria is prevalent among tenofovir-
treated patients, even with normal GFR [36, 37]. Urinary β2-
microglobulin is higher in patients with lower body weights,
suggesting that it is indeed a consequence of tenofovir
overdosing, and decreases upon tenofovir withdrawal [37].
Other manifestations of proximal tubulopathy in individual
patients include osteomalacia and decreased bone mass
due to phosphate wasting and/or calcitriol deficiency, since
calcitriol is synthesized by mitochondria in proximal tubules
[38–41]. Tenofovir causes bone toxicity in animal models,
when given at 6–12 times higher dose than recommended
for humans [42] but most studies comparing tenofovir
with other antiretroviral regimes have not found significant
diﬀerences in bone density between tenofovir-containing
treatment and control subjects or the diﬀerences have been
limited to certain bone sites [12, 43]. In this regard, it is
conceivable that bone toxicity is secondary to moderate to
severe proximal tubular dysfunction.
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Figure 1: Chemical structure of the three main nephrotoxic acyclic nucleotide analogs, adefovir, cidofovir and tenofovir, as well as less
nephrotoxic tenofovir derivatives under development. A lesser uptake by proximal tubular cells can be achieved by either esterifying the
compounds with an alkoxyalkyl group, in eﬀect disguising them as lysophospholipids (hexadecyloxypropyl-tenofovir, CMX157) or by
ribose-modification (GS-9148 and its oral prodrug GS-9131).
Tenofovir is associated with a small, but increased risk of
AKI [22]. This is the most dramatic consequence of tenofovir
nephrotoxicity. AKI may be observed even a few months
after starting tenofovir in predisposed patients. Tenofovir-
induced AKI is usually nonoliguric, but it may be oliguric,
and may require dialysis [23, 44]. Evidence of proximal
tubular dysfunction is usually present. After discontinuation
of the drug, renal function usually recovers, at least partially.
However, CKD requiring dialysis following AKI has been
described in a patient treated with tenofovir and cidofovir
[44].
The majority of studies did not find a significant higher
risk of proteinuria, CKD, or end-stage renal disease (ESRD)
requiring dialysis in HIV patients treated with tenofovir
compared to those receiving other antiretroviral drugs [12,
43, 45–48]. This is somewhat expected since CKD is a severe,
irreversible manifestation of kidney toxicity that may take
many years to develop. CKD may be asymptomatic until
GFR is <30mL/min/1.73m2. Thus, there is a real chance
that nephrotoxicitymight be overlooked, as serum creatinine
may not raise above the upper limit of normal until GFR is
<60mL/min/1.73m2. Patients should be trained to collect
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Figure 2: Tenofovir handling by proximal tubular cells and potential molecular mechanisms and clinical consequences of tenofovir
nephrotoxicity. (a) Tenofovir secretion by proximal tubular cells: 20 to 30% of tenofovir is excreted unchanged in the urine through
active secretion by proximal tubular cells. OAT1 is the main transporter taking tenofovir into the proximal tubular cell, although OAT3
also collaborates. Once inside this mitochondria-rich cell type, tenofovir must be extruded into the tubular lumen by MRP-2 and MRP-4.
Blocking tenofovir uptake by OAT1 may protect tubular cells by keeping intracellular tenofovir level low. Thus, probenecid is routinely
used to prevent cidofovir nephrotoxicity since cidofovir is also transported into tubular cells by OAT1. There is less experience preventing
tenofovir nephrotoxicity. A decreased GFR will increase plasma tenofovir levels and proximal tubular cell uptake through OAT1. Blocking
tenofovir extrusion by MRP-2 and MRP-4 by pharmacological interference may also boost tenofovir nephrotoxicity. OAT: organic acid
transporter; MRP: multidrug resistance protein. (b) Potential molecular mechanisms of tenofovir toxicity towards proximal tubular cells.
Proximal tubular cells are uniquely susceptible to tenofovir toxicity because they gave a complement of transporters that increase intracellular
concentrations of the drug, and they are rich inmitochondria. Tenofovir and other acyclic nucleotides decrease mtDNA content by inhibiting
mitochondrial DNA polymerase γ (POLG). This has been related to structural mitochondrial abnormalities, some of them visible even by
optical microscopy in cases of tenofovir nephrotoxicity, that include mitochondrial depletion, and wide changes in mitochondria size and
shape, with clumping, loss, and disorientation of cristae. In addition, mitochondrial injury may lead to apoptosis. Although tenofovir has not
been studied, cidofovir is known to induce proximal tubular cell apoptosis by leading to caspase activation [11]. The mitochondrial pathway
of apoptosis includes the release of mitochondrial proteins to the cytosol including cytochrome c (CytC), which is required for caspase
9 activation in the apoptosome Smac/Diablo, inhibitor of apoptosis proteins (IAPs), and apoptosis-inducing factor (AIF) that, among
other actions, causes DNA injury. These are potential mediators of tenofovir-induced tubular cell injury that deserve further study. (c)
Analytical and clinical consequences of tenofovir proximal tubular cell toxicity. Injured proximal tubular cells fail to perform their functions.
These include reabsorbing low-molecular-weight proteins (such as vitamin D-binding protein (DBP) and β2-microglobulin) through
the megalin-cubilin system (MCS), glucose through the sodium/glucose cotransporter 2 (SGLT2), aminoacids, phosphate and uric acid,
secreting H+ and synthesizing calcitriol by the action of mitochondrial 1α-hydroxylase on 25(OH) vitamin D reabsorbed from the tubular
lumenAsmore immediate consequences we may observe a variable mixture of low-molecular weight proteinuria, glycosuria, aminoaciduria,
hypophosphatemia, hypouricemia, renal tubular acidosis, and vitamin D insuﬃciency and even osteomalacia as a consequence both of
insuﬃcient calcitriol synthesis and urinary losses of 25(OH) vitamin D. Persistent tubular injury may promote tubular cell loss and eventual
decreased glomerular filtration and renal failure.
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Table 2: Biochemical features and time course of a case of tenofovir-associated Fanconi syndrome.
Before tenofovir
After 4 years
of tenofovir
One month
after tenofovir
Five months
after Tenofovir
Serum
Creatinine (mg/dL) 0.96 1.5 1.3 0.9
Glucose (mg/dL) 97 88 94 79
Uric acid (mg/dL) 8.4 1.2 1.8 3.4
Potassium (mmol/L 4.2 4.5 4.1 No data
Calcium (mg/dL) 9.1 8.5 9.2 9.2
Phosphorus (mg/dL) 3.8 2 3.2 No data
Total proteins (g/dL) No data 7.8 8.5 7.9
PTH (pg/mL) No data 128 55 27
Alkaline phosphatase
(UI/L)∗
No data 271 242 154
Urine and calculated
parameters
Glycosuria (mg/dL) Negative 1000 No data Negative
Proteinuria (mg/dL) Negative 50 53 Negative
Tubular reabsorption of
phosphate (%)
No data 34 59
Creatinine clearance
(mL/min)
86 26 40 No data
Albuminuria/creatinine
(mg/g)
10 937 303 No data
Light chains κ/λ (mg/dL) No data 4.2/4.1 2.5/1.7 0.6/<0.4
ß-2 microglobulin
(ug/24 h)
No data 4 4 No data
GGT<10UI/L at all time points.
Table 3: Predictors of significant renal function decline.
Preexisting renal impairment
Older age
Advanced HIV disease
Vasculometabolic disease
Concomitant use of nephrotoxic drugs or protease
inhibitors
Low body weight
ABCC2 gene (encoding the outward tenofovir
transporter MRP-2) polymorphisms
24 h urine specimens for creatinine clearance calculation,
since estimation of GFR based on serum creatinine by the
Modification of Diet in Renal Disease (MDRD) or Cockroft-
Gault formulae may underestimate the degree for renal
dysfunction if muscle mass, as is frequently the case in
HIV-infected individuals, is lower than their age and sex
standards [49]. Some observational cohort studies describing
low rates of renal dysfunction with tenofovir use were of
short duration [11, 20, 22, 50]. A recent meta-analysis of
13 studies (>5767 patients) reported a significantly faster
loss of kidney function (−5.4mL/min) in patients receiving
tenofovir compared with control subjects (mean diﬀerence
between groups in GFR loss estimated by the Cockroft-
Gault formula: 3.9mL/min; 95% confidence interval (CI),
2.1–5.7mL/min). However, a crucial piece of information,
the time in which those 3.9mL/min were lost, was missing
[22]. A significantly smaller degree of renal function loss was
reported in clinical trials than in observational studies (mean
decrease in eGFR 1.5 versus 5.45mL/min, resp.) [22]. Similar
results, albeit nonsignificant due to the smaller number of
studies, were observed when GFR was estimated by the
MDRD formula [22]. In this regard, mean rates of eGFR loss
as severe as−14.7mL/min in less than 1 year (48 weeks) were
reported in patients treated with tenofovir plus ritonavir-
boosted protease inhibitor regimes and this was significantly
greater than that in patients treated with tenofovir plus
nonnucleoside reverse transcriptase inhibitor regimes or
regimes without tenofovir (−4.5mL/min) [8]. Declines in
GFR averaging 7–10mL/min/year have been reported in
subjects treated with tenofovir [6]. This is not a modest rate
of eGFR decline. In fact, this rate of decline is observed in
diabetic or Fabry nephropathies and if maintained over time
it will lead to ESRD in 10 years [51]. As a reminder the
age-related estimated loss of GFR is −1mL/min/year. Slower
rates of decline in eGFR were observed in clinical trials of
selected populations and unselected cohorts. However, some
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of the estimates reporting lower rates of GFR loss are not
reliable due to a high rate of missing values during followup,
which might have been biased by the loss of patients with
nephrotoxicity [7]. For example, in a safety data analysis
from France, Germany, and Italy values for serum creatinine
were available at baseline for 2790 patients, but follow-up
data were available only for 1704 patients: nearly 40% of
patients lacked follow-up creatinine values [7].
Cardiovascular disease is now a leading cause of morbid-
ity and mortality in HIV patients. This may be related to an
increased prevalence of traditional cardiovascular risk factors
as well as HIV-specific factors associated with antiretroviral
therapy, chronic inflammation, and direct viral eﬀects [52].
Tenofovir nephrotoxicity may impact cardiovascular risk by
decreasing GFR and impairing the activation of vitamin D
in proximal tubules. Both a decreased GFR and vitamin
D deficiency are associated to increased cardiovascular risk
[53, 54].
4. Incidence and Prevalence of
Tenofovir Nephrotoxicity
Two studies have demonstrated tubular dysfunction with
tenofovir in 17–22% of tenofovir-treated patients (versus
6 and 12% of HAART-treated or -naive HIV patients)
[55, 56]. Some reports identified a trend toward higher
incidence of hypophosphatemia in patients on tenofovir
(incidence of serum phosphate <2mg/dL: 16.7 per 100
person-years among tenofovir-treated patients versus 8.0
per 100 person-years in those without tenofovir; prevalence
9.8% among tenofovir-treated, 6.7% among nontenofovir,
HAART-treated and 2.6% among treatment-naive, HIV-
infected individuals) [55, 57] recognizing that hypophos-
phatemia is relatively common in HIV patients [58]. Glyco-
suria was found in 5 out of 7 nondiabetic patients biopsied
for tenofovir nephrotoxicity with increased serum creatinine
and residual diuresis [23]. This is a high percentage com-
pared with the finding of non-diabetic glycosuria in 2% of
tenofovir-treated patients with normal GFR [54], suggesting
that dipstick glycosuria may be a cost-eﬀective screening test
for serious tenofovir-induced kidney injury.
The risk diﬀerence for AKI for tenofovir compared to
control subjects was estimated to be 0.7% (95%CI 0.2–1.2%)
in a recent metaanalysis [22].
A retrospective study of >1000 HIV-infected patients on
tenofovir identified 1% whose sCr increased >120 μmol/L
[59]. A 4-year followup of 10,343 tenofovir-treated patients
disclosed serious renal adverse events in 0.5% and an increase
in serum creatinine ≥0.5mg/dL in 2.2% of patients [7]. The
SCOLTA observational study of 754 HIV-infected, tenofovir-
treated patients found a 2.5% incidence of creatinine ele-
vations over 1.5-fold the upper limit of normal in a mean
followup of 19.5 months [60, 61]. The cut-oﬀ values used in
these studies to define nephrotoxicity clearly underestimated
this adverse eﬀect. As a reminder, current AKIN criteria
define AKI as an increment of serum creatinine of 0.3mg/dL
in 48 h [62]. Thus, an increase in serum creatinine but
within normal limits (e.g., from 0.7 to 1.0mg/dL) is already
indicative of serious renal injury.
5. Pathogenesis
The proximal tubular cell is the main target of tenofovir
toxicity due to its complement of cell membrane transporters
that favor tenofovir accumulation. Current evidence suggests
that mitochondria are the target organelles of tenofovir
cytotoxicity. Proximal tubular cells account for most of the
tubular transport of molecules, reabsorbing over 200 g ClNa,
1 kg glucose, and other molecules from the tubular lumen
every day. Energy for this transport is provided by a high
number of mitochondria. Proximal tubular cells are also
rich in cell membrane transporters [63] (Figure 2). Proximal
tubule mitochondria activate 25 dihydroxycholecalciferol by
1α hydroxylation, therefore yielding the active metabolite of
vitamin D, calcitriol. Furthermore, they release the ammonia
required by distal segments to secrete protons into the urine.
Thus, mitochondrial injury will impair molecular transport,
vitamin D activation, and urinary acidification (Figure 2).
Mitochondria assembly needs the cooperation of both the
nuclear and the mitochondrial genomes. Thus mitochon-
drial dysfunction may be the result of (a) mitochondrial
genes that are defective or missing, (b) relevant nuclear
genes that are defective or missing, or (c) normal assembled
mitochondria that are damaged and lose function.
Tenofovir is an acyclic nucleotide phosphonate, like ade-
fovir and cidofovir. Cidofovir is a recognized proximal tubu-
lar cell toxin, and the high incidence of toxicity prompted
discontinuation of clinical trials for adefovir in the treatment
of HIV infection [44, 64, 65]. Initial cell culture studies did
not disclose significant tenofovir toxicity to human proximal
renal tubules with the tests and culture conditions employed.
Minimal mtDNA depletion and nonsignificant reductions in
the mitochondrial protein cytochrome c oxidase were noted
with tenofovir [3]. In this regard, tenofovir is considered a
weaker inhibitor of mitochondrial DNA polymerase γ than
adefovir and cidofovir [6]. However, more recent studies
employing cell viability assays disclosed a 100-fold increase
in cytotoxicity at 120 h in cells expressing OAT1 versus cells
lacking the transporter [26] (Figure 2).
HIV transgenic mice exposed to tenofovir showed ultra-
structural mitochondrial abnormalities and decreased prox-
imal tubular mtDNA, but not optical microscopy changes
[27]. No ultrastructural mitochondrial abnormalities were
observed in control HIV transgenics or in tenofovir-treated
wild-type (WT) mice. However, there were no diﬀerences
in proximal tubule mtDNA between HIV transgenics and
WT, either in the presence or absence of tenofovir. This
observation does not support the hypothesis that mtDNA
depletion, a complication of HIV infection, might prime
for more severe mitochondrial dysfunction if exposed to
tenofovir [66].
Rather, additional factors related to HIV infection might
be relevant. In the absence of HIV, rats exposed to teno-
fovir developed proximal tubular dilatation, ultrastructural
mitochondrial abnormalities, depleted mtDNA, depressed
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respiratory chain enzyme expression [24], and specific
downregulation of proximal tubular sodium-phosphorus
cotransporter, sodium/hydrogen exchanger 3, and aquaporin
2 [25].Morphological evidence ofmitochondrial toxicitywas
also found in human biopsies of tenofovir nephrotoxicity
[23]. Tenofovir is an adenosine analogue, like didanosine.
In contrast to didanosine, which induced significant hepatic
mtDNA depletion in rats and mice, tenofovir had no liver
eﬀects, confirming the importance of specific proximal
tubular transporters in increasing the intracellular tenofovir
concentrations to toxic levels in proximal tubules [24, 27].
The extent to which mitochondrial damage is responsible
for proximal tubular cell loss and the mechanisms of such
an eﬀect remain unclear. Inhibition of mtDNA polymerase γ
encoded by POLG has been proposed to have a central role
in tenofovir-related mitochondrial toxicity [67]. Inherited
POLG abnormalities lead to decreased mtDNA content and
accumulation of mtDNA defects [68]. Depletion of mtDNA
may lead to fatty acid and dicarboxylic acid accumula-
tion, lacticacidosis and ROS damage, and both resistance
and sensitivity to apoptosis [69–73]. However, in nucleo-
side reverse transcriptase inhibitor-induced lipodystrophy,
mtDNA-dependent mitochondrial functions are preserved
despite severe mtDNA depletion and the presence of apop-
tosis did not correlate with mtDNA content [71].
Damage to mtDNA has been well studied in adefovir
nephrotoxicity [64]. Renal biopsies from patients with
adefovir-induced AKI revealed proximal tubule necrosis con-
taining dysmorphic and enlarged mitochondria, deficiency
of mtDNA encoded enzymes, and a 30–60% reduction in
mtDNA in injured tubules. However, the in vitro toxicity
index based on the relative rates of mtDNA and nuclear DNA
replication underpredicts the toxicity of some drugs, suggest-
ing that factors other than inhibition of DNA polymerase
γ be responsible for nephrotoxicity [74]. Kidney mtDNA
depletion was associated with HIV infection and concurrent
tenofovir/didanosine therapy but not to tenofovir use alone,
while kidney ultrastructural mitochondrial abnormalities
were seen with tenofovir use [75].
Interestingly, mitochondria are key organelles in apop-
totic cell death [76]. In this regard, cidofovir induced OAT1-
dependent, probenecid-sensitive, and caspase-dependent
apoptosis specifically in proximal tubules [44]. Whether
tenofovir activates similar pathways should be studied
(Figure 2(b)).
6. Pathology
There are several reports on the underlying pathology of
human tenofovir nephrotoxicity [23, 75, 77]. Detailed renal
pathology of cases biopsied for AKI or for proteinuria and
mild renal dysfunction were recently provided [23]. The
major renal biopsy finding was proximal tubular injury,
ranging from diﬀuse and severe to mild and localized.
This was associated with varying degrees of chronic tubu-
lointerstitial scarring (i.e., tubular atrophy and interstitial
fibrosis) [23]. Either findings of acute tubular injury or
findings of chronic injury may predominate, leading to a
diagnosis of acute or chronic tubulointerstitial nephropathy,
respectively. By light microscopic proximal tubular changes
resembled toxic acute tubular necrosis and included luminal
ectasia, irregular luminal contours, prominent nucleoli, and
loss of brush border. A distinctive finding was prominent
eosinophilic intracytoplasmic inclusions representing giant
mitochondria, as confirmed by ultrastructural studies [23].
In some proximal tubular cells, the number of mitochon-
dria was markedly reduced, consistent with mitochondrial
depletion. Mitochondria varied widely in size and shape.
Many enlarged mitochondria displayed prominent clump-
ing, loss, and disorientation of cristae. Kidney mtDNA
depletion was associated with HIV infection and concurrent
tenofovir/didanosine therapy but not tenofovir use alone,
while kidney ultrastructural mitochondrial abnormalities
were seen with tenofovir use [74].
In tenofovir-treated mice no disruption of glomeruli
or proximal tubules was observed by light microscopy.
Ultrastructurally in proximal tubules from tenofovir-treated
HIV transgenic mice but not from wild-type mice included
there was an increased number and irregular shape of
mitochondria with sparse fragmented cristae [27].
7. Prediction, Prevention, and Treatment
of Nephrotoxicity
The overall safety profile of tenofovir is quite positive. Thus,
a prediction of who is at risk of nephrotoxicity is required
to adequately manage those patients. Multivariate analysis of
postmarketing clinical data showed that advanced age, low
body weight, higher serum creatinine levels before starting
tenofovir treatment, comorbidities (diabetes, hypertension,
HCV coinfection) concomitant nephrotoxic medications,
advanced HIV infection (low CD4 counts, AIDS), and,
in some studies, male sex were risk factors for tenofovir-
induced GFR reduction [7, 8, 61] (Table 3).
The odds of developing significant renal function reduc-
tion were 3.7 times higher for patients receiving tenofovir
plus ritonavir-boosted protease inhibitor regimes than for
those receiving tenofovir plus nonnucleoside reverse tran-
scriptase inhibitor-based therapy, even adjusting for HIV
load [8]. Underlying renal disease with low GFR enhances
the risk for tenofovir toxicity by decreasing tenofovir renal
clearance and increasing the amount of tenofovir in the
circulation and proximal tubular cells [78]. Dose reduction is
indicated if GFR is low, but thismay be diﬃcult to implement
when a single pill contains several antiretrovirals. Certain
ABCC2 gene (encoding the outward tenofovir transporter
MRP2) polymorphisms were associated with tenofovir-
induced renal dysfunction [56].
Recent guidelines from the HIV Medicine Association of
the IDSA recommend at least biannual monitoring of renal
function, serum phosphorus, proteinuria, and glycosuria in
HIV patients receiving tenofovir with GFR <90mL/min/
1.73m2, other comorbid diseases or cotreated with protease
inhibitors, due to the potential risk of nephrotoxicity [22,
28, 79, 80]. Mild cases of tenofovir-associated nephropathy
may be detected testing urine for features of proximal tubule
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injury and by measuring bone density [22]. Urinary features
of proximal tubular dysfunction include glycosuria, the pres-
ence of increased amounts of low-molecular-weight proteins
such as β2-microglobulin or light chains, aminoaciduria,
and inappropriate amounts of uric acid or phosphorus,
coupled with a reduced phosphate reabsorption rate. In
addition serum uric acid and phosphate are low and serum
bicarbonate may decrease (Table 2).
The most eﬀective treatment of tenofovir nephrotoxicity
is stopping tenofovir. Features of nephrotoxicity frequently
improve following discontinuation of the drug. In a followup
of 20 ± 26 months after discontinuation of tenofovir
following AKI, roughly 50% of patients completely recovered
renal function to baseline levels, including a patient who
had required dialysis for 4 months [23]. Other patients
had partial recovery of renal function, from a mean peak
sCr 5.6 ± 3.8 to sCr 1.5 ± 0.3mg/dL. Renal function
and features of proximal tubular dysfunction improve over
weeks to months [13, 81] (Table 2). Early detection of
nephrotoxicity and tenofovir withdrawal are key to avoid
irreversible tubulointerstitial damage.
8. Future Developments:
towards Nephroprotection
Theoretically nephroprotection could be achieved by pre-
venting tenofovir entry into proximal tubular cells, facilitat-
ing its exit or administering drugs that protect tubular cells
from injury. Probenecid, an inhibitor of hOAT1, is used to
prevent cidofovir nephrotoxicity and may also protect from
tenofovir [29, 30, 66]. However, 56% of patients had side
eﬀects ascribed to probenecid when used to prevent the prox-
imal tubular toxicity of cidofovir, which were dose limiting in
7% [31]. Rosiglitazone, a peroxisome proliferator-activated
receptor-gamma agonist that induces the expression of
many proximal tubular cell transporters, protected rats
from tenofovir-induced renal failure and proximal tubular
dysfunction [25]. However, concerns over the cardiovascular
safety of rosiglitazone have led to its withdrawal from
European markets [82]. Clearly more research is needed on
nephroprotective strategies using drugs.
Another approach is to modify the tenofovir molecule to
decrease proximal tubular uptake. Low oral bioavailability,
renal toxicity, and poor cell penetration are limitations of
acyclic nucleotide phosphonates. These undesirable features
can be eliminated by esterifying the compounds with an
alkoxyalkyl group, in eﬀect disguising them as lysophos-
pholipids [2]. Among other advantages, in this modified
form, drugs are not recognized by the transport mechanisms
that cause their accumulation in renal proximal tubular
cells. As a consequence, they lack nephrotoxicity in rats.
A member of this class of molecules, hexadeciloxypropyl-
tenofovir (CMX157), is now in clinical development [83]. In
addition, novel ribose-modified NtRTI are currently being
evaluated in the clinic. These molecules are less eﬃciently
transported into and less cytotoxic to proximal tubular
cells than acyclic nucleotides [26]. These include GS-9148
and its oral prodrug GS-9131 [26]. Hopefully the clinical
development of any of these strategies will result in the
availability of less cytotoxic albeit eﬀective NtRTI drugs.
9. Summary
Tenofovir nephrotoxicity is characterized by proximal tubu-
lar cell injury. This may result in partial or complete Fanconi
syndrome, AKI or CKD. Drug withdrawal is the main
therapeutic option. This usually results in improvement
of clinical manifestations of kidney injury, which may be
only partial. Thus, prevention of nephrotoxicity by careful
monitoring of high-risk populations is paramount. Proximal
tubular cells are particularly sensitive to the toxic eﬀects
of tenofovir due to their unique set of cell membrane
transporters that favor entry of the drug. In this regard,
the design of novel, less cytotoxic drugs is centered on
chemical modifications that limit entry into proximal cells.
Mitochondria are targets of tenofovir cytotoxicity. However
the precise molecular mechanisms of injury are unclear.
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